MorphoSys receives US patent for anticancer compound
The new patent has a scheduled expiry date in 2028, not including any potential regulatory extensions. The HuCAL-derived, fully human antibody is currently being tested in a Phase
Isomorphic Labs has raised $5bn in a Series C financing round to support the development of its AI platform and advance its therapeutic candidates towards clinical evaluation.